Clinical
Trials
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
- Study to Evaluate Efficacy and Safety of Zanubrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Condition:LymphomaMolecule:Zanubrutinib
- Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCondition:Leukemia, LymphomaMolecule:Zanubrutinib
- A Study to Investigate Zanubrutinib in Chinese Patients With B-cell LymphomaCondition:LymphomaMolecule:Zanubrutinib
- Study of the Safety and Pharmacokinetics of Zanubrutinib in Subjects With B-Cell Lymphoid MalignanciesCondition:Lymphoma, Leukemia, MyelomaMolecule:Zanubrutinib
- Zanubrutinib in Combination With Tislelizumab in Subjects With B-cell MalignanciesCondition:Lymphoma, LeukemiaMolecule:Zanubrutinib + Tislelizumab
- Comparison of Efficacy and Safety of Tislelizumab Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With Non-Small Cell Lung Cancer (NSCLC)Condition:Lung CancerMolecule:Tislelizumab
- A Study of Tislelizumab Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma (ESCC)Condition:Esophageal CancerMolecule:Tislelizumab
- Phase 3 Study of Tislelizumab Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)Condition:Liver CancerMolecule:Tislelizumab
- Study of Tislelizumab in Patients With Previously Treated Unresectable Hepatocellular Carcinoma (HCC)Condition:Liver CancerMolecule:Tislelizumab
- A Study of Tislelizumab in Patients With Relapsed or Refractory Mature T- and NK- NeoplasmsCondition:LymphomaMolecule:Tislelizumab
See All Trials
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.